Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

Abstract Objective Pembrolizumab has become an integral first line therapeutic agent for non-small cell lung cancer (NSCLC), but its potential predictive role in clinical and molecular characteristics remains to be clarified. Accordingly, we performed a systematic review and meta-analysis to evaluat...

Full description

Bibliographic Details
Main Authors:	Wenjie Liu, Gengwei Huo, Peng Chen
Format:	Article
Language:	English
Published:	BMC 2023-05-01
Series:	BMC Cancer
Subjects:	Pembrolizumab Non-small cell lung cancer Predictor Meta analysis
Online Access:	https://doi.org/10.1186/s12885-023-10959-3

Similar Items

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
by: Wenjie Liu, et al.
Published: (2022-06-01)

Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
by: Gengwei Huo, et al.
Published: (2022-04-01)

Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
by: Rocío Jiménez Galán, et al.
Published: (2023-01-01)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
by: Hiromi Matsumoto, et al.
Published: (2022-01-01)

Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients
by: Yi Tong Vincent Aw, et al.
Published: (2023-03-01)

Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report
by: Shoki Sato, et al.
Published: (2019-10-01)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
by: Yan Li, et al.
Published: (2022-09-01)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
by: Khanh Toan Nguyen, et al.
Published: (2023-08-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
by: Kazutaka Hosoya, et al.
Published: (2021-04-01)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
by: Panpan Jiang, et al.
Published: (2021-09-01)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
by: Ou Yamaguchi, et al.
Published: (2021-02-01)

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
by: Ethan A. Burns, et al.
Published: (2022-12-01)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2021-07-01)

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis
by: Beibei Yang, et al.
Published: (2023-02-01)

Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
by: Takeshi Masuda, et al.
Published: (2022-06-01)

Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review
by: Xinsheng Li, et al.
Published: (2021-08-01)

Immunotherapy in first-line treatment of recurrent non-small cell lung cancer
by: E. O. Rodionov, et al.
Published: (2019-12-01)

Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment
by: Luísa Biscaglia Miquelotti, et al.
Published: (2023-01-01)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
by: Yixin Zhou, et al.
Published: (2020-03-01)

Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells
by: Zhenzhen eHui, et al.
Published: (2015-12-01)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
by: Wentao Tian, et al.
Published: (2023-09-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024-02-01)

Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced  Non-small Cell Lung Cancer and Its Therapeutic Effect
by: Yun WANG, et al.
Published: (2021-03-01)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
by: Jiatao Liao, et al.
Published: (2021-09-01)

Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
by: Rocío Jiménez Galán, et al.
Published: (2021-09-01)

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial
by: Weigang Dong, et al.
Published: (2024-03-01)

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
by: Hisao Imai, et al.
Published: (2021-10-01)

Pembrolizumab for non‐small cell lung cancer with central nervous system metastases: A two‐case report
by: Mingyi Di, et al.
Published: (2019-02-01)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023-06-01)

Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab
by: Zahi Hiba, MD, et al.
Published: (2022-10-01)

Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma
by: Haiyan Li, et al.
Published: (2024-02-01)

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
by: Ghislain Bérard, et al.
Published: (2023-03-01)

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab
by: Yoshiko Mizushina, et al.
Published: (2021-08-01)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
by: Teppei Sugano, et al.
Published: (2019-02-01)

Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib
by: Liling HUANG, et al.
Published: (2021-10-01)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
by: Hiroaki Akamatsu, MD, PhD, et al.
Published: (2021-07-01)

Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
by: Sachiko Matsumoto, et al.
Published: (2020-07-01)

Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports
by: Fadi Nasr, et al.
Published: (2019-06-01)

Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management
by: Davide Fattore, et al.
Published: (2022-08-01)